Abstract:Background: Minimal hepatic encephalopathy (MHE) is an early and reversible form of hepatic encephalopathy. The documentations on the treatment with probiotics are inconsistent. The present meta-analysis was to verify the role of probiotics in the treatment of cirrhotic patients with MHE. Data sources: Seven electronic databases were searched for relevant randomized controlled trials (RCTs) published until July 2015. The effects of probiotics on serum ammonia, endotoxin, and MHE were evaluated. Results: A total of 14 RCTs (combined n = 1132) were included in the meta-analysis. When probiotics were compared to placebo or no treatment, probiotics were more likely to reduce values in the number connection test (NCT; week 4: MD = -30.25, 95% CI: -49.85 to -10.66), improve MHE (week 4: OR = 0.18, 95% CI: 0.07 to 0.47; week 12: OR = 0.15, 95% CI: 0.07 to 0.32), and prevent overt HE progression (week 4: OR = 0.22, 95% CI: 0.07 to 0.67) in patients with liver cirrhosis. When probiotics was compared to lactulose, probiotics tended to reduce serum ammonia levels (week 4: MD = -0.33 mu mol/L, 95% CI: -5.39 to 4.74; week 8: MD = 6.22 mu mol/L, 95% CI: -24.04 to 36.48), decrease NCT (week 8: MD = 3.93, 95% CI: -0.72 to 8.58), improve MHE (week 4: OR = 0.93, 95% CI: 0.45 to 1.91; week 12: OR = 0.73, 95% CI: 0.35 to 1.51) and prevent the development of overt HE (week 4: OR = 0.96, 95% CI: 0.17 to 5.44; week 12: OR = 2.7, 95% CI: 0.50 to 14.64) in patients with liver cirrhosis. However, lactulose appears to be more effective in reducing NCT values as compared to probiotics (week 4: MD = 6.7, 95% CI: 0.58 to 12.82). Conclusion: Probiotics can decrease serum ammonia and endotoxin levels, improve MHE, and prevent overt HE development in patients with liver cirrhosis. (C) 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Nonpharmacologic Management of Hepatic Encephalopathy: An Update

Nontraditional Treatment of Hepatic Encephalopathy

Navigating the Gut-brain Axis: Insights into the Pathogenesis of Hepatic Encephalopathy

Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions

Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment

The Role of Intestinal Bacteria and Gut–Brain Axis in Hepatic Encephalopathy

Fecal Microbiota Transplantation for Treating Hepatic Encephalopathy: Experimental and Clinical Evidence and Possible Underlying Mechanisms

Fecal microbiota transplantation in the treatment of hepatic encephalopathy: A perspective

Hepatic encephalopathy – recent advances in treatment and diagnosis

Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis

Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments

Systems of care that improve outcomes for people with hepatic encephalopathy

Prophylaxis of hepatic encephalopathy: current and future drug targets

Hepatic encephalopathy: current challenges and future prospects

The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas

The assessment and management of cirrhotic patients with encephalopathy

Effect of Probiotic Treatment on Cirrhotic Patients with Minimal Hepatic Encephalopathy: A Meta-Analysis.

A Meta-Analysis of Microbiome Therapies for Hepatic Encephalopathy

Advances in the diagnosis and treatment of hepatic encephalopathy

Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain

Advancements in Interventional Radiology for Managing Hepatic Encephalopathy: A Comprehensive Review